WNY Asset Management LLC Makes New $800,000 Investment in Pfizer Inc. $PFE

WNY Asset Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 33,220 shares of the biopharmaceutical company’s stock, valued at approximately $800,000.

Other hedge funds have also modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at $26,000. Keb Asset Management LLC acquired a new position in shares of Pfizer during the second quarter valued at $26,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. increased its position in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC bought a new stake in Pfizer during the 4th quarter worth about $31,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PFE. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price objective for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Guggenheim cut their price target on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, BMO Capital Markets reduced their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Pfizer Trading Down 1.0%

NYSE PFE opened at $28.00 on Friday. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market cap of $159.62 billion, a P/E ratio of 36.85 and a beta of 0.34. The stock’s 50-day moving average is $25.49 and its 200-day moving average is $26.29.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.